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Although the HIV pandemic is not a new phenomenon, 
there are still significant gaps in knowledge that influ-
ence progress in prevention and treatment strategies. 
Most of these gaps involve the first few days and weeks 
of infection, i.e. the period of acute HIV infection.
Acute HIV infection (AHI) is usually defined as the time 
from entry of the virus into the body to completion of 
seroconversion, while early-stage HIV infection gener-
ally refers to the interval between seroconversion and 
the establishment of the viral load set point. The mag-
nitude of the viral set point is prognostic for disease 
progression.1
Tests such as rapid HIV tests are initially negative in 
acute HIV as there is a delayed immune response. Se-
roconversion can occur as late as 6 months after ex-
posure, while detectable levels of viraemia and p24 
antigenaemia develop over the first 3 - 4 weeks of 
infection.2,3 
Evolution of symptoms of the acute retroviral syn-
drome usually coincides with high levels of viraemia 
and the host’s initial immunological response. The 
classic mononucleosis-like symptoms of acute HIV-1 
infection (fever, joint pain, inguinal lymphadenopathy 
and night sweats) may last several days to weeks and 
are found in at least 47% of patients with AHI.4,5 
Several studies suggest that individuals with acute HIV 
infection can be identified in sexually transmitted infec-
tion (STI) clinics and perhaps other high-risk settings.5,6 
The detection of acute HIV infection is important not 
only from a research and prevention point of view but 
because it may also allow for early treatment that 
could modify the natural history of the disease.7 
MEDLINE and PubMed databases were searched using 
the keywords ‘Acute HIV’, ‘natural history of HIV’, ‘HIV 
in Africa’ and ‘immunology of HIV’. More recent articles 
were focused on, i.e. those published after 2000. 
The diagnosis of acute HIV infection is important from 
a public health point of view.8 Patients are highly in-
fectious and HIV transmission occurs readily owing to 
a massive viral burden in the blood and genital secre-
tions.9 Acute HIV may therefore account for a dispro-
portionate amount of HIV transmission. Patients may 
be unaware that they are infected and continue to en-
gage in risky behaviour, putting others at risk. The dif-
ferential d  iagnosis of an unexplained viral syndrome 
in a sexually active adult should always include acute 
HIV.10 
 
A study in heterosexual couples in the Rakai district of 
Uganda showed an increased risk of HIV transmission 
in the period just following HIV acquisition. In 10 out 
of 23 initially uninfected couples both partners sero-
converted within the same 10-month follow-up period. 
A ‘per-act transmission rate’ of 0.0082 was calculated 
for this ‘early transmission’ group by dividing the total 
number of transmission events by the total number of 
sex acts reported by the 23 couples. A much smaller 
transmission rate was obtained for couples who were 
serodiscordant at enrollment.11
Another study from Botswana showed that identifica-
tion of acute HIV was possible in a public health set-
ting. This was viewed as an important part of reducing 
the epidemic in this country in combination with early 
use of HAART, risk reduction counselling, partner noti-
fication and contact tracing.12
The natural history of HIV-1 has been well charac-
terised in industrialised countries. A cohort study of 
homosexual men showed a steep decline in CD4+ T-
cell counts after seroconversion. HIV RNA load at the 
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Health care providers are faced with a number of challenges with regard to acute HIV infection. The first of 
these is recognition, because the acute retroviral symptoms mimic a number of other viral infections. The sec-
ond challenge is treatment, as treating early HIV has a number of benefits and risks both on an individual and 
a public health level. This review hopes to address some of these questions. 
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first HIV-seropositive visit (~3 months after serocon-
version) was highly predictive of AIDS, with prognosis 
correlating with subsequent HIV RNA measurements. 
The CD4+ T-cell decline was generally more severe in 
patients with higher CD4+ T-cell count levels before 
infection, which may reflect greater HIV replication.1 
A subgroup of patients from a Swiss and Australian 
cohort showed that both the incubation period of AHI 
(time between HIV infection and AHI) and duration of 
AHI were associated with the late prognosis of HIV in-
fection. The incubation period of AHI was independ-
ently associated with progression towards AIDS.13
Information regarding the natural history of HIV-1 in-
fection in Africa is limited. In a prospective cohort study 
of female sex workers in Mombasa, Kenya, the survival 
rate was similar to that for HIV-1-infected individu-
als in developed countries before the introduction of 
highly active antiretroviral therapy (HAART). This was 
supported by a review of African studies from Uganda 
and Malawi. A higher viral load set point and more se-
vere acute HIV-1 illness predicted faster progression to 
death. Disease in an African cohort, however, did not 
progress faster to AIDS than an industrialised country 
cohort.14,15  
It is estimated that between 40% and 90% of patients 
with AHI experience an acute retroviral syndrome 
(ARS). Symptoms usually occur 2 - 6 weeks after ex-
posure to HIV-1 and typically last 14 days, but may 
persist for as long as 10 weeks.4 
The significance of the severity of seroconversion symp-
toms is not known, but the presence of seroconversion 
symptoms has been correlated with more rapid disease 
progression.4,14
Common symptoms include fever (>80 - 90%), fatigue 
(>70 - 90%), pharyngitis (50 - 70%), weight loss, night 
sweats (50%), lymphadenopathy (40 - 70%), arthralgia 
or myalgia (50 - 70%), headache (32 - 70%), skin rash 
(>40 - 80%), and nausea, vomiting and diarrhoea (30 
- 60%). The rash is typically maculopapular and usu-
ally involves the trunk. It may be difficult to detect in 
black African cohorts. Other less frequent symptoms 
include aseptic meningitis (24%), oral ulcers (10 - 
20%) and genital ulcers (5 - 15%), while frequent non-
specific laboratory findings include leukopenia (40%), 
thrombocytopenia (45%) or mild transaminitis (21%).16 
Other unusual presentations include myopericarditis, 
acute renal failure, cranial nerve VII palsy, radiculopa-
thy and opportunistic infections such as candidiasis, 
cytomegalovirus infection, and Pneumocystis jirovecii 
pneumonia.4
The nonspecific nature of acute retroviral symptoms 
and the extensive differential diagnosis often make the 
identification of this syndrome challenging. It is im-
portant to consider this diagnosis in order to obtain an 
appropriate history, perform an appropriate risk factor 
assessment, perform a thorough physical examination, 
and order appropriate diagnostic tests.4,17
In an article by Fiscus et al., AHI was considered to be 
present if HIV RNA results were positive and one of the 
following conditions were met: (i) rapid antibody tests 
both negative; (ii) rapid antibody tests discordant and 
Western blot results negative or indeterminate; and 
(iii) rapid antibody tests discordant and Western blot 
results weakly positive with subsequent band evolu-
tion.18 
In contrast, Hoen et al. used three laboratory criteria to 
confirm the diagnosis of primary HIV infection: (i) posi-
tive p24 antigenaemia; (ii) negative HIV enzyme-linked 
immunosorbent assay (ELISA) or positive ELISA in a pa-
tient who could be confirmed HIV negative within the 
past 3 months; and (iii) <3 bands in the Western blot 
test.19 
The p24 band is usually the first to become positive in 
the Western blot test during seroconversion. If this is 
the only band present the HIV antibody test is consid-
ered to be indeterminate. This result should be corre-
lated with the HIV-1 plasma RNA level.4
As CD4+ T-cell counts can briefly decrease during acute 
infection, they are generally not reliable markers of im-
mune status during the first 6 months of infection.4
The value of initiating antiretroviral therapy during 
AHI is uncertain. There are no randomised control tri-
als examining the long-term effects of early treatment 
on the clinical course and prognosis of HIV infection. 
Results from studies are conflicting, and some evidence 
shows that early treatment may not alter the viral set 
point consistently following interruption.4,20
The benefits and risks of initiating therapy for AHI con-
tinue to be discussed. Potential benefits include the 
control of acute retroviral symptoms, prevention of ab-
normal helper T-cell function and reduction in the pace 
of decline, delaying or preventing decreased immune 
function and vulnerability to opportunistic infections, 
decreasing the initial viral load set point, which may 
decrease transmission, limiting viral evolution and di-
versity, potential slowing of the rate of disease pro-
gression among patients with a genetic predisposition, 
and decrease in the size of the latent HIV pool.4,20 
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Risks include increased cost, adverse effects and ab-
normal metabolic findings, drug resistance, long-term 
challenges to adherence, and unknown long-term tox-
icities or expected duration of benefit.4 
A US study in 47 patients showed that initiation of 
HAART within 90 days of HIV-1 infection was associ-
ated with reduced HIV-1 virus levels, improved CD4+ 
T-cell counts and immune conservation, decreased op-
portunistic infections, and decreased frequency of res-
piratory and mucocutaneous conditions when used for 
78 weeks. Rapid progression to AIDS also was avoided. 
However, side-effects of combination therapy were 
commonly reported in this study.21
iMMUnOlOGical EFFEcTS OF aRT in PaTiEnTS  
WiTH aHi
The limited benefit of antiretroviral therapy initiated 
during AHI may be explained to some degree by the 
early depletion of lymphocyte reservoirs in the gastro-
intestinal tract reported in some studies. This may also 
help to explain the conflicting evidence between early 
observations demonstrating apparent immunological 
benefit with early antiretroviral treatment with the in-
ability to control viral replication after treatment in-
terruption.20
Only a few reports describe the effects of HAART on 
HIV-specific T-cell responses during acute HIV infec-
tion.22,23 However, limitations such as small sample size, 
short duration of follow-up and lack of concomitant 
virological data need to be taken into account when 
interpreting these results.23 In a cohort of 16 HIV-1-
infected individuals who received their diagnosis at 
the time of seroconversion and who were started on 
HAART within 72 hours, a robust HIV-1-specific CD4+ 
T-cell proliferative response was observed and viraemia 
was contained.22 
One prospective cohort study followed up participants 
from the time of acute infection and examined differ-
ent virological profiles related to various treatment 
interventions. No correlation was observed between 
baseline viral load and HIV-specific CD4+ and CD8+ 
T-cell responses. Subjects who started HAART at the 
time of acute infection had no better HIV-specific T-
cell responses than those who started therapy after 
seroconversion, and the absence of any treatment or 
the incomplete virological control did not prevent the 
development of an HIV-specific CD4+ T-cell response. 
This may imply that early therapy aimed at preserving 
the HIV-specific immune response may not be neces-
sary in all subjects.23 
WHEn TO STaRT TREaTMEnT
The period during which treatment for acute HIV should 
be given is not clear. Benefits have being shown up to 
3 - 4 months after infection, but long-term effects on 
morbidity and mortality are unknown. Most clinicians 
would choose to treat within the first 6 months after 
seroconversion.4 
Guidelines for initiation of therapy for patients in 
whom acute HIV-1 infection has been diagnosed are 
often vague and lack consensus.
The US Department of Health and Human Serv-
ices (DHHS) guidelines recommend consideration of 
treatment for patients who received their diagnosis 
<6 months after infection. These guidelines consider 
treatment to be optional as clinical trials information is 
limited and benefits and risks of treatment need to be 
weighed up when considering initiating treatment.24 
The British HIV Association (BHIVA) guidelines recog-
nise that there are inconsistent study results on treat-
ment in acute HIV. The justification for treating AHI is 
to preserve specific anti-HIV immune responses, reduce 
morbidity associated with high viraemia and CD4+ T-
cell depletion and reduce the risk of HIV transmission. 
These guidelines recommend treatment of AHI for the 
relief of symptoms of ARS with neurological involve-
ment, for any AIDS-defining illness or a CD4+ T-cell 
count persistently <200 cells/ml. BHIVA guidelines rec-
ommend that there is currently insufficient evidence to 
support treatment for other indications.25 
Both the International AIDS Society–USA Panel recom-
mendations and South African HIV Clinicians Society 
Guidelines do not currently recommend ART for AHI 
as there is no definitive evidence supporting this ther-
apy.26,27 
Reasons not to treat patients with AHI include no 
proven efficacy of treatment in this period, drug toxic-
ity, and the potential development of drug resistance. 
Treatment should only be considered in a research trial 
or in the presence of very severe symptoms after con-
sultation with an expert HIV clinician.27 
EXPEcTED OUTcOMES OF EaRlY TREaTMEnT
The time taken to achieve viral suppression in AHI may 
be dependent on a number of host factors. High initial 
viral loads may prolong the time to viral suppression, 
while the relatively intact immune system and lower 
total body viral burden in patients may decrease time 
to suppression.4 
Subjects from a multicentre Acute Infection and Early 
Disease Research Program cohort were enrolled in a 
study within 6 months of HIV seroconversion and self-
selected whether to initiate HAART. CD4+ T-cell counts 
at 24, 48 and 72 weeks were compared between treat-
ed and untreated groups. Initiation of HAART within 2 
weeks of seroconversion was associated with viral load 
and CD4+ T-cell count benefits for 24 weeks after ter-
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mination of HAART. Later initiation of HAART showed 
less benefit in CD4+ T-cell counts, but viral load benefit 
lasted till week 72. The limitations of the study includ-
ed a lack of random allocation of treatment, variation 
in duration of treatment, lack of statistical significance 
of the CD4+ T-cell count and viral load benefits at 72 
weeks, the small sample size, and the need for longer 
follow-up to assess the durability of the apparent ben-
efit.28
The application of HAART treatment for AHI is lim-
ited by high costs, drug resistance, and drug-related 
toxicities. New treatment options such as supervised 
treatment interruption (STI) are being investigated as 
alternative options. With the STI strategy, HAART is in-
termittently stopped once viral load has been reduced 
to a low level, in order to boost natural immunity by 
brief exposure to the virus.29
In a longitudinal open-label study of STI in 14 patients 
with acute HIV-1 infection, only transient control of vi-
raemia was achieved after drug interruption. A gradual 
increase in viraemia and decline in CD4+ T-cell counts 
was observed in most patients, even after a year or 
more of viral containment.29
Data from the SMART (Strategies for Management of 
Anti-Retroviral Therapy) trial provided evidence that 
episodic use of ART based on CD4+ T-cell levels was 
inferior to use of continuous therapy for treatment-
experienced patients and therefore should not be rou-
tinely recommended. There was no evidence that in-
terrupting drug exposure was related to fewer adverse 
events such as myocardial infarction, stroke and renal 
and liver disease.30 
The follicular dendritic cell network (FDC) in lymphoid 
tissues is the major site of HIV storage in the presymp-
tomatic and late stages of disease. In a review of 21 
patients from 4 sites, there was no correlation between 
the duration of infection and accumulation of HIV into 
the FDC network. The data suggested that a large pool 
of infectious virus is established soon after infection 
and that initiation of antiretroviral therapy when 
symptoms of primary HIV infection are recognised is 
unlikely to prevent substantial accumulation of virus 
in the FDC network. Early treatment might, however, 
maintain immune responses by preserving CD4+ T cells 
and reducing the FDC virus pool.31 
While it is important on an individual and public health 
level to identify acute HIV infections, uncertainty still 
remains regarding the treatment of these identified 
infections. On a case-by-case basis there may be ben-
efit in treating individuals who present with severe 
symptoms or persistently low CD4+ T-cell counts to 
maintain immune system integrity. With regard to the 
public health benefits, the reduction in transmission 
needs to be weighed up against the cost and toxicity 
of widespread treatment.
Other strategies such as vaccines and microbicides also 
need to be considered in this context in the prevention 
of transmission and infections.
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